Theravance Biopharma (NASDAQ:TBPH) Stock Price Passes Above 50-Day Moving Average Following Analyst Downgrade

Theravance Biopharma, Inc. (NASDAQ:TBPH)’s share price crossed above its fifty day moving average during trading on Tuesday after Weiss Ratings upgraded the stock from a hold (c) rating to a hold (c+) rating. The stock has a fifty day moving average of $16.95 and traded as high as $17.10. Theravance Biopharma shares last traded at $17.06, with a volume of 251,659 shares traded.

A number of other equities analysts have also commented on the company. Zacks Research upgraded Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. Wall Street Zen downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. JonesTrading downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday, June 29th. BTIG Research lowered Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Monday, June 29th. Finally, HC Wainwright cut Theravance Biopharma from a “buy” rating to a “neutral” rating and increased their price objective for the company from $15.00 to $17.00 in a research report on Tuesday, July 7th. Eight research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $19.40.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 13,314 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $16.39, for a total value of $218,216.46. Following the completion of the transaction, the senior vice president owned 232,457 shares of the company’s stock, valued at $3,809,970.23. This represents a 5.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 37,799 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $17.00, for a total value of $642,583.00. Following the completion of the sale, the insider owned 9,174,453 shares of the company’s stock, valued at $155,965,701. This represents a 0.41% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 350,011 shares of company stock worth $6,008,309. 7.65% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Arrowstreet Capital Limited Partnership acquired a new position in Theravance Biopharma in the third quarter worth about $10,611,000. California State Teachers Retirement System boosted its holdings in Theravance Biopharma by 1,550.9% during the second quarter. California State Teachers Retirement System now owns 672,911 shares of the biopharmaceutical company’s stock valued at $11,439,000 after purchasing an additional 632,150 shares in the last quarter. Pacer Advisors Inc. acquired a new stake in Theravance Biopharma during the fourth quarter valued at approximately $6,342,000. Janus Henderson Group PLC grew its stake in shares of Theravance Biopharma by 214.8% in the 4th quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock valued at $7,493,000 after purchasing an additional 273,288 shares during the period. Finally, Two Sigma Investments LP grew its stake in shares of Theravance Biopharma by 1,199.9% in the 3rd quarter. Two Sigma Investments LP now owns 231,272 shares of the biopharmaceutical company’s stock valued at $3,377,000 after purchasing an additional 213,480 shares during the period. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Trading Down 0.2%

The stock has a fifty day moving average price of $16.95 and a 200-day moving average price of $16.46. The firm has a market capitalization of $883.68 million, a price-to-earnings ratio of 16.85 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.18). Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. The company had revenue of $20.73 million during the quarter, compared to analyst estimates of $22.49 million. On average, equities analysts expect that Theravance Biopharma, Inc. will post 1.56 EPS for the current year.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.